MA41494B1 - Composés benzoxaborole substitués en position 4 et utilisations associées - Google Patents

Composés benzoxaborole substitués en position 4 et utilisations associées

Info

Publication number
MA41494B1
MA41494B1 MA41494A MA41494A MA41494B1 MA 41494 B1 MA41494 B1 MA 41494B1 MA 41494 A MA41494 A MA 41494A MA 41494 A MA41494 A MA 41494A MA 41494 B1 MA41494 B1 MA 41494B1
Authority
MA
Morocco
Prior art keywords
compounds substituted
associated uses
benzoxaborole compounds
ch2ch2ch3
ch2ch3
Prior art date
Application number
MA41494A
Other languages
English (en)
French (fr)
Other versions
MA41494A (fr
Inventor
Jacob J Plattner
Xianfeng Li
David Barros-Aguirre
Ilaria Giordano
Carlos Alemparte-Gallardo
M R K Alley (Dickon)
Vincent Hernandez
Original Assignee
Glaxosmithkline Ip No 2 Ltd
Anacor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55409879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41494(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip No 2 Ltd, Anacor Pharmaceuticals Inc filed Critical Glaxosmithkline Ip No 2 Ltd
Publication of MA41494A publication Critical patent/MA41494A/fr
Publication of MA41494B1 publication Critical patent/MA41494B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/08Antibacterial agents for leprosy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/04Esters of boric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA41494A 2015-02-12 2016-02-11 Composés benzoxaborole substitués en position 4 et utilisations associées MA41494B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15382054 2015-02-12
EP15382055 2015-02-12
EP15382056 2015-02-12
PCT/IB2016/050775 WO2016128948A1 (en) 2015-02-12 2016-02-12 4 -substituted benzoxaborole compounds and uses thereof

Publications (2)

Publication Number Publication Date
MA41494A MA41494A (fr) 2017-12-19
MA41494B1 true MA41494B1 (fr) 2020-10-28

Family

ID=55409879

Family Applications (2)

Application Number Title Priority Date Filing Date
MA41494A MA41494B1 (fr) 2015-02-12 2016-02-11 Composés benzoxaborole substitués en position 4 et utilisations associées
MA041495A MA41495A (fr) 2015-02-12 2016-02-11 Composés benzoxaborole et leurs utilisations

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA041495A MA41495A (fr) 2015-02-12 2016-02-11 Composés benzoxaborole et leurs utilisations

Country Status (36)

Country Link
US (3) US10774096B2 (https=)
EP (2) EP3256479B1 (https=)
JP (2) JP2018506540A (https=)
KR (2) KR20170117158A (https=)
CN (2) CN107548398A (https=)
AU (3) AU2016217508A1 (https=)
BR (2) BR112017017213A2 (https=)
CA (2) CA2976308A1 (https=)
CL (2) CL2017002059A1 (https=)
CO (2) CO2017008809A2 (https=)
CR (2) CR20170371A (https=)
CY (1) CY1123687T1 (https=)
DK (1) DK3256479T3 (https=)
DO (2) DOP2017000188A (https=)
EA (2) EA036516B1 (https=)
ES (1) ES2821951T3 (https=)
HR (1) HRP20201597T1 (https=)
HU (1) HUE051113T2 (https=)
IL (2) IL253865A0 (https=)
LT (1) LT3256479T (https=)
MA (2) MA41494B1 (https=)
MX (2) MX379057B (https=)
MY (1) MY194004A (https=)
NZ (1) NZ734379A (https=)
PE (2) PE20171432A1 (https=)
PH (2) PH12017501427A1 (https=)
PL (1) PL3256479T3 (https=)
PT (1) PT3256479T (https=)
RS (1) RS60885B1 (https=)
SG (2) SG11201706510YA (https=)
SI (1) SI3256479T1 (https=)
SM (1) SMT202000565T1 (https=)
TW (2) TW201702250A (https=)
UA (1) UA120527C2 (https=)
WO (2) WO2016128949A1 (https=)
ZA (1) ZA201705456B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160251380A1 (en) * 2013-08-09 2016-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Tricyclic benzoxaborole compounds and uses thereof
RS63461B1 (sr) 2017-05-08 2022-08-31 Glaxosmithkline Ip Dev Ltd Sanfetrinem ili njegova so ili estar za upotrebu u lečenju mikobakterijske infekcije
MX2020005464A (es) 2017-11-30 2020-12-03 Boragen Inc Compuestos de benzoxaborol y formulaciones de los mismos.
WO2020041200A1 (en) 2018-08-18 2020-02-27 Boragen Inc. Solid forms of substituted benzoxaborole and compositions thereof
CN110441344B (zh) * 2019-06-25 2020-09-29 北京大学 一种基于固体核磁共振技术检测rna结构的方法
EP4384527A4 (en) * 2022-06-23 2025-09-03 Micurx Pharmaceuticals Inc PRODRUGS OF BORON COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS
CA3239096A1 (en) * 2022-06-23 2023-12-28 Shanghai Micurx Pharmaceutical Co., Ltd. Methods and uses of boron compounds in the treatment of nontuberculous mycobacterium infections and pharmaceutical compositions for treatment of same
KR20240150582A (ko) 2023-04-08 2024-10-15 김태서 맥세이프 배터리팩을 포함한 아이폰 케이스

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411587D0 (en) * 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
EP0947498B1 (en) 1996-12-02 2004-09-15 Chisso Corporation Optically active nitro alcohol derivatives, optically active amino alcohol derivatives, and process for preparing the same
US7446236B2 (en) 2002-12-02 2008-11-04 Solvias Ag Catalytic hydrogenation of carbon-heteroatom double bonds
EP2343304B1 (en) 2005-02-16 2015-06-10 Anacor Pharmaceuticals, Inc. Biocidal boronophthalide compounds
EP1856113B1 (en) 2005-03-08 2016-01-06 Agency for Science, Technology and Research Chiral bisoxazoline catalysts
KR20080110984A (ko) 2005-12-30 2008-12-22 아나코르 파마슈티칼스 인코포레이티드 보론함유 소분자
TWM325238U (en) * 2006-12-29 2008-01-11 Universal Scient Ind Co Ltd Voltage regulator and voltage regulating system
KR100848491B1 (ko) 2007-01-16 2008-07-28 영진약품공업주식회사 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법
JO3396B1 (ar) * 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
WO2010080558A1 (en) 2008-12-17 2010-07-15 Anacor Pharmaceuticals, Inc. Polymorphs of (s)-3-aminomethyl-7-(3-hydroxy-propoxy)-3h-benzo[c][1,2] oxaborol-1-ol
US20110124597A1 (en) * 2009-09-25 2011-05-26 Anacor Pharmaceuticals, Inc. Boron containing small molecules
ES2710105T3 (es) * 2010-04-07 2019-04-23 Glaxosmithkline Llc Proceso para preparar benzoxaboroles
SI3251678T1 (sl) * 2010-09-07 2022-01-31 Anacor Pharmaceuticals, Inc. Derivati benzoksaborola za zdravljenje bakterijskih okužb
JP6031122B2 (ja) * 2011-12-22 2016-11-24 ミクウルク ファーマシューティカルズ,インコーポレイテッド 抗微生物療法のための三環式ホウ素化合物
CN102739587B (zh) 2012-06-16 2014-05-21 天地融科技股份有限公司 音频数据传输方法
KR101636431B1 (ko) 2013-07-30 2016-07-05 동아에스티 주식회사 트리사이클릭 벤즈옥사보롤 화합물, 이의 제조방법 및 용도
US20160251380A1 (en) 2013-08-09 2016-09-01 Glaxosmithkline Intellectual Property (No.2) Limited Tricyclic benzoxaborole compounds and uses thereof

Also Published As

Publication number Publication date
US10774096B2 (en) 2020-09-15
TW201643173A (zh) 2016-12-16
DOP2017000189A (es) 2018-02-15
WO2016128948A1 (en) 2016-08-18
CN107531730A (zh) 2018-01-02
CL2017002059A1 (es) 2018-03-16
EP3256480A1 (en) 2017-12-20
SG11201706511TA (en) 2017-09-28
US20180044353A1 (en) 2018-02-15
PH12017501428A1 (en) 2018-01-15
DOP2017000188A (es) 2017-09-15
IL253864A0 (en) 2017-09-28
AU2016217508A1 (en) 2017-09-28
HRP20201597T1 (hr) 2020-12-25
LT3256479T (lt) 2020-12-28
NZ734379A (en) 2023-06-30
BR112017017213A2 (pt) 2018-04-03
AU2016217507B2 (en) 2019-03-14
BR112017017211A2 (pt) 2018-04-03
RS60885B1 (sr) 2020-11-30
US20180037595A1 (en) 2018-02-08
MX2017010414A (es) 2018-05-11
SMT202000565T1 (it) 2020-11-10
CR20170372A (es) 2017-10-19
IL253865A0 (en) 2017-10-31
EP3256479B1 (en) 2020-07-29
PL3256479T3 (pl) 2021-06-14
DK3256479T3 (da) 2020-11-02
KR20170117158A (ko) 2017-10-20
CL2017002060A1 (es) 2018-03-16
CA2976030A1 (en) 2016-08-18
CY1123687T1 (el) 2022-03-24
SG11201706510YA (en) 2017-09-28
EA201791671A1 (ru) 2018-02-28
JP2018506540A (ja) 2018-03-08
EA036516B1 (ru) 2020-11-18
MA41495A (fr) 2017-12-19
PE20171432A1 (es) 2017-09-26
AU2016217507A1 (en) 2017-09-28
CN107531730B (zh) 2020-08-07
TWI730953B (zh) 2021-06-21
CN107548398A (zh) 2018-01-05
EP3256479A1 (en) 2017-12-20
US11214582B2 (en) 2022-01-04
JP2018506538A (ja) 2018-03-08
EA201791667A1 (ru) 2018-02-28
US20210053996A1 (en) 2021-02-25
MX379057B (es) 2025-03-10
MY194004A (en) 2022-11-07
HUE051113T2 (hu) 2021-01-28
ZA201705456B (en) 2019-10-30
CR20170371A (es) 2018-01-22
MA41494A (fr) 2017-12-19
PT3256479T (pt) 2020-10-22
SI3256479T1 (sl) 2020-11-30
WO2016128949A1 (en) 2016-08-18
CO2017008816A2 (es) 2017-11-10
AU2020256369A1 (en) 2020-11-12
JP6771472B2 (ja) 2020-10-21
TW201702250A (zh) 2017-01-16
BR112017017211B1 (pt) 2023-04-25
IL253864B (en) 2021-07-29
MX2017010413A (es) 2018-05-11
UA120527C2 (uk) 2019-12-26
CO2017008809A2 (es) 2017-11-10
CA2976308A1 (en) 2016-08-18
PE20171348A1 (es) 2017-09-13
PH12017501427A1 (en) 2018-01-15
CA2976030C (en) 2023-09-26
ES2821951T3 (es) 2021-04-28
KR20170117156A (ko) 2017-10-20

Similar Documents

Publication Publication Date Title
MA41494B1 (fr) Composés benzoxaborole substitués en position 4 et utilisations associées
MA41134A (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MA41625A (fr) Composés de benzazépine dicarboxamide
MA38227A1 (fr) Nouveaux composés bicycliques et leur utilisation en tant qu'agents antibactériens et inhibiteurs de ?-lactamase
MA30232B1 (fr) Inhibiteurs de kinase bases sur l'hydantoine
MA52486B1 (fr) Pyridazinones utilisés en tant qu'inhibiteurs de parp7
MA53124B1 (fr) Agents de dégradation sélectifs des récepteurs des oestrogènes
MA38284B1 (fr) Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
MA46038A (fr) Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale
MA45888A1 (fr) Inhibiteurs de tyrosine kinase de bruton
MA34308B1 (fr) Triazolopyridines substituées
MA37762B1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MA37764A1 (fr) Composés n-alkyltriazole utilisés comme antagonistes de lpar
MA34331B1 (fr) Composés pyrazole comme inhibiteurs du récepteur sigma
MA38661A1 (fr) Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine
EP2091328A4 (en) SPIROPIPERIDININHIBITORS OF BETA-SECRETASE FOR THE TREATMENT OF ALZHEIMER DISEASE
MA35748B1 (fr) Fluorométhyl-5,6-dihydro-4h-[1,3]oxazines
WO2019007696A1 (en) NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS
MA31366B1 (fr) Derives d'azetidine et leur utilisation comme antagonistes de prostaglandine e2
MA27629A1 (fr) Dérivés du benzènesulfonamide, leur procédé de préparation et leur utilisation pour le traitement de la douleur.
SA522441650B1 (ar) مثبطات فوسفوينوسيتيد 3-كيناز الموضعية
MA31863B1 (fr) Dérivés de pyrazole comme inhibiteurs de 5-lo